---
input_text: 'Neurocognitive and somatic stabilization in pediatric patients with severe
  Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin
  receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase
  1-2 trial. BACKGROUND: Mucopolysaccharidosis (MPS) Type I (MPSI) is caused by mutations
  in the gene encoding the lysosomal enzyme, alpha-L-iduronidase (IDUA), and a majority
  of patients present with severe neurodegeneration and cognitive impairment. Recombinant
  IDUA does not cross the blood-brain barrier (BBB). To enable BBB transport, IDUA
  was re-engineered as an IgG-IDUA fusion protein, valanafusp alpha, where the IgG
  domain targets the BBB human insulin receptor to enable transport of the enzyme
  into the brain. We report the results of a 52-week clinical trial on the safety
  and efficacy of valanafusp alpha in pediatric MPSI patients with cognitive impairment.
  In the phase I trial, 6 adults with attenuated MPSI were administered 0.3, 1, and
  3 mg/kg doses of valanafusp alpha by intravenous (IV) infusion. In the phase II
  trial, 11 pediatric subjects, 2-15 years of age, were treated for 52 weeks with
  weekly IV infusions of valanafusp alpha at 1, 3, or 6 mg/kg. Assessments of adverse
  events, cognitive stabilization, and somatic stabilization were made. Outcomes at
  52 weeks were compared to baseline. RESULTS: Drug related adverse events included
  infusion related reactions, with an incidence of 1.7%, and transient hypoglycemia,
  with an incidence of 6.4%. The pediatric subjects had CNS involvement with a mean
  enrollment Development Quotient (DQ) of 36.1+-7.1. The DQ, and the cortical grey
  matter volume of brain, were stabilized by valanafusp alpha treatment. Somatic manifestations
  were stabilized, or improved, based on urinary glycosaminoglycan levels, hepatic
  and spleen volumes, and shoulder range of motion. CONCLUSION: Clinical evidence
  of the cognitive and somatic stabilization indicates that valanafusp alpha is transported
  into both the CNS and into peripheral organs due to its dual targeting mechanism
  via the insulin receptor and the mannose 6-phosphate receptor. This novel fusion
  protein offers a pharmacologic approach to the stabilization of cognitive function
  in MPSI. TRIAL REGISTRATION: Clinical Trials.Gov, NCT03053089 . Retrospectively
  registered 9 February, 2017; Clinical Trials.Gov, NCT03071341 . Registered 6 March,
  2017.'
raw_completion_output: |-
  primary_disease: Mucopolysaccharidosis Type I (MPSI)

  medical_actions: intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha) administration; cognitive stabilization assessment; somatic stabilization assessment

  symptoms: severe neurodegeneration; cognitive impairment; infusion related reactions; transient hypoglycemia; reduced Development Quotient (DQ); decreased cortical grey matter volume of brain; increased urinary glycosaminoglycan levels; increased hepatic and spleen volumes; limited shoulder range of motion

  chemicals: insulin receptor antibody-iduronidase fusion protein (valanafusp alpha); alpha-L-iduronidase (IDUA)

  action_annotation_relationships: intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha) TREATS severe neurodegeneration IN Mucopolysaccharidosis Type I (MPSI); intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha) TREATS cognitive impairment IN Mucopolysaccharidosis Type I (MPSI); intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha) TREATS infusion related reactions IN Mucopolysaccharidosis Type I (MPSI); intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha) TREATS transient hypoglycemia IN Mucopolysaccharidosis Type I (MPSI); cognitive stabilization assessment ASSESSES cognitive impairment IN Mucopolysaccharidosis Type I (MPSI); somatic stabilization assessment ASSESSES urinary glycosaminoglycan levels IN Mucopolysaccharidosis Type I (MPSI); somatic stabilization assessment ASSESSES hepatic and spleen volumes IN Mucopolysaccharidosis Type I (MPSI); somatic stabilization assessment ASSESSES shoulder range of motion IN Mucopolysaccharidosis Type I (MPSI)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  somatic stabilization assessment ASSESSES shoulder range of motion IN Mucopolysaccharidosis Type I (MPSI)

  ===

extracted_object:
  primary_disease: MONDO:0017385
  medical_actions:
    - intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein
      (valanafusp alpha) administration
    - cognitive stabilization assessment
    - somatic stabilization assessment
  symptoms:
    - severe neurodegeneration
    - HP:0100543
    - infusion related reactions
    - transient hypoglycemia
    - reduced Development Quotient (DQ)
    - decreased cortical grey matter volume of brain
    - increased urinary glycosaminoglycan levels
    - increased hepatic and spleen volumes
    - limited shoulder range of motion
  chemicals:
    - insulin receptor antibody-iduronidase fusion protein (valanafusp alpha)
    - alpha-L-iduronidase (IDUA)
  action_annotation_relationships:
    - subject: intravenous brain-penetrating insulin receptor antibody-iduronidase
        fusion protein
      predicate: TREATS
      object: HP:0002180
      qualifier: MONDO:0017385
      object_qualifier: severe
      subject_extension: valanafusp alpha
      object_extension: severe
    - subject: intravenous brain-penetrating insulin receptor antibody-iduronidase
        fusion protein
      predicate: TREATS
      object: HP:0100543
      qualifier: MONDO:0017385
      subject_extension: valanafusp alpha
      object_extension: cognitive impairment
    - subject: intravenous brain-penetrating insulin receptor antibody-iduronidase
        fusion protein
      predicate: TREATS
      object: infusion related reactions
      qualifier: MONDO:0017385
      subject_extension: valanafusp alpha
    - subject: intravenous brain-penetrating insulin receptor antibody-iduronidase
        fusion protein
      predicate: TREATS
      object: transient hypoglycemia
      qualifier: MONDO:0017385
      subject_extension: valanafusp alpha
    - subject: cognitive stabilization assessment
      predicate: ASSESSES
      object: HP:0100543
      qualifier: MONDO:0017385
    - subject: somatic stabilization assessment
      predicate: ASSESSES
      object: urinary glycosaminoglycan levels
      qualifier: MONDO:0017385
    - subject: somatic stabilization assessment
      predicate: ASSESSES
      object: hepatic and spleen volumes
      qualifier: MONDO:0017385
    - subject: somatic stabilization assessment
      predicate: ASSESSES
      object: shoulder range of motion
      qualifier: MONDO:0017385
named_entities:
  - id: MONDO:0001586
    label: mucopolysaccharidosis type I
  - id: MONDO:1012617
    label: Mucopolysaccharidosis Type I (MPS I)
  - id: CHEBI:60285
    label: DOPE
  - id: MAXO:0001521
    label: nasal administration
  - id: MONDO:0011758
    label: Mucopolysaccharidosis type I Hurler (MPSIH)
  - id: MAXO:0000747
    label: hematopoietic stem cell transplantation (HSCT)
  - id: MAXO:0000487
    label: clinical assessment (growth measurement, kyphosis and genu velgum evaluation)
  - id: HP:0002808
    label: kyphosis
  - id: HP:0001376
    label: limited joint mobility
  - id: HP:0008807
    label: acetabular dysplasia
  - id: MAXO:0010034
    label: Corneal transplantation
  - id: HP:0007957
    label: Corneal clouding
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: HP:0000238
    label: Hydrocephalus
  - id: MAXO:0000068
    label: transplantation
  - id: MAXO:0000004
    label: surgery
  - id: MAXO:0000526
    label: clinical examination
  - id: CHEBI:143889
    label: glycosaminoglycan (GAG)
  - id: HP:0004322
    label: short stature
  - id: HP:0005619
    label: thoracolumbar kyphosis
  - id: HP:0000943
    label: dysostosis multiplex
  - id: MONDO:0011759
    label: Hurler-Scheie syndrome
  - id: HP:0001387
    label: joint stiffness
  - id: HP:0000403
    label: recurrent otitis media
  - id: HP:0001999
    label: facial dysmorphism
  - id: HP:0002781
    label: Upper airway obstruction
  - id: HP:0001638
    label: Cardiomyopathy
  - id: MAXO:0001479
    label: Allogeneic hematopoietic stem cell transplantation
  - id: MAXO:0001001
    label: Gene therapy
  - id: CHEBI:58187
    label: Alginate
  - id: CHEBI:53412
    label: PLL (Poly-L-lysine)
  - id: CHEBI:50594
    label: Carbon nanotubes
  - id: HP:0007663
    label: Reduced visual acuity
  - id: MAXO:0000016
    label: cellular therapy
  - id: CHEBI:19226
    label: Tm
  - id: MONDO:0017385
    label: mucopolysaccharidosis type I (MPSI) Hurler
  - id: MAXO:0000018
    label: Biomarker assessment
  - id: HP:0001138
    label: Optic neuropathy
  - id: HP:0000488
    label: Retinopathy
  - id: MONDO:0019052
    label: Inborn errors of metabolism
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:33310
    label: MCT (NE)
  - id: HP:0001367
    label: joint disease
  - id: HP:0002652
    label: skeletal dysplasia
  - id: HP:0000618
    label: vision impairments
  - id: HP:0000365
    label: hearing impairments
  - id: MONDO:0007147
    label: Obstructive sleep apnea syndrome (OSAS)
  - id: MAXO:0000915
    label: Overnight polysomnography (PSG)
  - id: HP:0002104
    label: Apnea
  - id: HP:0040213
    label: Hypopnea
  - id: MAXO:0010033
    label: Umbilical cord blood transplantation
  - id: MONDO:0009290
    label: Pompe Disease
  - id: HP:0005162
    label: Left ventricular failure
  - id: HP:0011675
    label: Conduction abnormalities
  - id: HP:0001677
    label: Coronary artery disease
  - id: HP:0001433
    label: Hepatosplenomegaly
  - id: HP:0033126
    label: Necrosis
  - id: CHEBI:46793
    label: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(amino[polyethylene glycol]-
      2000) (DSPE-PEG)
  - id: CHEBI:17754
    label: Glycerol
  - id: CHEBI:15377
    label: Water
  - id: CHEBI:27881
    label: Resveratrol
  - id: HP:0010864
    label: severe mental retardation
  - id: CHEBI:82467
    label: Evans blue
  - id: MONDO:0006249
    label: mucopolysaccharidoses (MPS)
  - id: CHEBI:232920
    label: Alginate-poly-L-lysine-alginate (APA)
  - id: HP:0000708
    label: Behavioral abnormalities
  - id: HP:0033429
    label: Neuroinflammation
  - id: MAXO:0001525
    label: Intravenous administration
  - id: HP:6000847
    label: cardiac mass
  - id: HP:0012393
    label: Allergic reactions
  - id: HP:0001268
    label: Cognitive decline
  - id: HP:0000388
    label: Otitis media
  - id: HP:0000750
    label: Language delays
  - id: MAXO:0000479
    label: Orthopedic surgeries
  - id: HP:0011947
    label: Respiratory infections
  - id: CHEBI:28088
    label: Genistein
  - id: MAXO:0000506
    label: Non-invasive ventilation
  - id: HP:0002091
    label: Restrictive lung disease
  - id: HP:0001513
    label: Obesity
  - id: HP:0000822
    label: High blood pressure
  - id: HP:0001626
    label: Cardiovascular abnormalities
  - id: CHEBI:18376
    label: dermatan sulfate
  - id: CHEBI:28815
    label: heparan sulfate
  - id: CHEBI:37397
    label: chondroitin sulfate
  - id: CHEBI:15971
    label: heparan sulfate (HS)
  - id: CHEBI:17053
    label: dermatan sulfate (DS)
  - id: CHEBI:16991
    label: DNA
  - id: HP:0001385
    label: Hip dysplasia
  - id: HP:0001263
    label: Cognitive delay
  - id: CHEBI:50693
    label: Milrinone
  - id: MAXO:0000011
    label: Physical therapy
  - id: HP:0003423
    label: Thoracolumbar kyphoscoliosis
  - id: HP:0002970
    label: Genua vara
  - id: HP:0002650
    label: Scoliosis
  - id: HP:0002857
    label: Genua valga
  - id: HP:0003311
    label: Odontoid hypoplasia
  - id: HP:0100543
    label: cognitive impairment
  - id: HP:0002180
    label: neurodegeneration
